GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Days Sales Outstanding

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Days Sales Outstanding : 76.84 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Days Sales Outstanding?

Tarsus Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2024 was $23.25 Mil. Tarsus Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $27.61 Mil. Hence, Tarsus Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 76.84.

The historical rank and industry rank for Tarsus Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

TARS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 116.56   Med: 347.72   Max: 347.72
Current: 116.56

During the past 6 years, Tarsus Pharmaceuticals's highest Days Sales Outstanding was 347.72. The lowest was 116.56. And the median was 347.72.

TARS's Days Sales Outstanding is ranked worse than
71.78% of 893 companies
in the Biotechnology industry
Industry Median: 73.34 vs TARS: 116.56

Tarsus Pharmaceuticals's Days Sales Outstanding declined from Mar. 2023 (91.25) to Mar. 2024 (76.84).


Tarsus Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Tarsus Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals Days Sales Outstanding Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial - - - - 347.72

Tarsus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.25 - 261.51 76.70 76.84

Competitive Comparison of Tarsus Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Tarsus Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tarsus Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's Days Sales Outstanding falls into.



Tarsus Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Tarsus Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0 + 16.621) / 1 ) / 17.447*365
=16.621 / 17.447*365
=347.72

Tarsus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding (Q: Mar. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )*Days in Period
=( (16.621 + 29.885) / 2 ) / 27.614*365 / 4
=23.253 / 27.614*365 / 4
=76.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tarsus Pharmaceuticals  (NAS:TARS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Tarsus Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Executives
Bobak R. Azamian director, 10 percent owner, officer: President and CEO 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo officer: Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg director 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield officer: Chief Human Resources Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl officer: General Counsel 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow officer: See Remarks TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein officer: Chief Financial Officer 24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan officer: Chief Operating Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook officer: V.P., Clinical Affairs 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann director, 10 percent owner 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873